Yahoo Finance6d
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC Pharmaceuticals SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 07, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing ...
ETF Daily News6d
ORIC Pharmaceuticals (ORIC) Projected to Post Quarterly Earnings on Monday
In other ORIC Pharmaceuticals news, CEO Jacob Chacko sold 24,660 shares of the company’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of ...
Yahoo Finance23d
ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that ...
manilatimes6d
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 07, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address ...
ETF Daily News18d
ORIC Pharmaceuticals’ (ORIC) Buy Rating Reiterated at HC Wainwright
Shares of ORIC stock opened at $7.68 on Friday. ORIC Pharmaceuticals has a 1-year low of $6.33 and a 1-year high of $16.65. The firm’s 50-day simple moving average is $9.27 and its 200-day ...
Business Insider23d
ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates
Reported encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with androgen receptor inhibitors in patients with mCRPC Entered into clinical ...
Business Insider23d
Oppenheimer Keeps Their Buy Rating on Oric Pharmaceuticals (ORIC)
In a report released today, Matthew Biegler from Oppenheimer reiterated a Buy rating on Oric Pharmaceuticals (ORIC – Research Report), with a price target of $15.00. The company’s shares ...
Nasdaq23d
ORIC Pharmaceuticals Reports Promising Early Data for ORIC-944 and ORIC-114; Collaborates with Johnson & Johnson on NSCLC Treatment
ORIC Pharmaceuticals, Inc. announced positive early safety and efficacy results from its ongoing dose escalation trial of ORIC-944, combined with androgen receptor inhibitors for metastatic ...
Yahoo Finance23d
ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address ...
manilatimes23d
ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates
Reported encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with androgen receptor inhibitors in patients with mCRPC Entered into clinical trial ...
Finanznachrichten23d
ORIC Pharmaceuticals: ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates
Reported encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with androgen receptor inhibitors in patients with mCRPC Entered into clinical ...
The Bakersfield Californian24d
ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and ...
Reported encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with androgen receptor inhibitors in patients with mCRPC Entered into clinical ...